Last checked at 2 Mar 2020 15:35
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Director/PDMR's Dealing
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, announces the following dealing in the Company's ordinary shares of £0.01 each in the Company ("Ordinary Shares") by Carsten Schroeder, PDMR and Non-Executive Director. The Company was notified on 28 February 2020.
PDMR | Date of purchase | Number of shares purchased | Purchase price | Total shares held | % ISC held followingpurchase |
Carsten Schroeder | 28 February 2020 | 9,000 | £0.541 | 9,000 | 0.00014% |
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Carsten Schroeder | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Non-Executive Director | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Oncimmune Holdings plc | |||
b)
| LEI
| 213800HCYIWT6YPI1I02 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each
| |||
Identification code | ISIN: GB00BYQ94H38 | ||||
b)
| Nature of the transaction
| Purchase of shares | |||
c)
| Price(s) and volume(s) | ||||
Price | Volume | ||||
0.541 GBP | 9,000 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | Same as above | ||||
- Price | |||||
e)
| Date of the transaction
| 28 February 2020 | |||
f)
| Place of the transaction
| London stock exchange, AIM | |||
For further information:
Oncimmune Holdings plc
Andrew Stewart, General Counsel and Company Secretary
contact@oncimmune.com